Maritoclax, a specific MCL1 inhibitor, reversed irinotecan/SN38 resistance in FBW7‐deficient CRC cells and xenograft models, synergizing with irinotecan to suppress tumor growth. This evidence concerns the gene MCL1 and neoplasm.